This phase II trial is comparing the safety and effectiveness of a specialised form of radiotherapy (radioligand therapy, 177Lu-PSMA-617) given in combination with chemotherapy, versus chemotherapy alone, for patients with newly diagnosed prostate cancer.
This trial is treating patients with prostate cancer.
This is a systemic therapy and radiotherapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
Eligible patients will be randomised to receive 177Lu-PSMA every 6 weeks for 2 cycles, followed by docetaxel (6 weeks later) every 3 weeks for 6 cycles; OR docetaxel (on its own) every 3 weeks for 6 cycles.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More